This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

epidemiology

Globally, 5% of TB cases were estimated to have had MDR-TB in 2013 (3.5% of new and 20.5% of previously treated TB cases).

Drug resistance surveillance data show that an estimated 480 000 people developed MDR-TB in 2013 and 210 000 people died.

Extensively drug-resistant TB (XDR-TB) has been reported by 100 countries in 2013.

  • on average, an estimated 9% of people with MDR-TB have XDR-TB.

If all notified TB patients (6.1 million, new and previously treated) had been tested for drug resistance in 2013, an estimated 300 000 cases of MDR-TB would have been detected.

  • 136 000 of the estimated 300 000 MDR-TB patients who could have been detected were diagnosed and notified
  • this represents a tripling in MDR-TB detection compared with 2009.

27 high burden countries for MDR-TB have been recognised which accounts for more than 85% of cases

  • highest number of cases were reported from China, India, and the Russian Federation
  • the highest proportions are found in eastern Europe and Central Asia, with around 20% of new cases and 50% of previously treated cases having MDR-TB

In the UK

  • 1.4% of new and 5.7% of previously treated patients have MDR-TB
    • 89% of these patients are born outside the United Kingdom

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.